cyrilzakka/clinical-trials huggingface dataset:
Association Between Some Polymorphisms in Apelin/ Apelin Receptor Genes and Coronary Artery Disease in Syrian Patients

The apelin-APJ signaling pathway has emerged as an important novel mediator of cardiovascular control and blood pressure homeostasis. Genetic variation in apelin and its receptors likely contributes to essential hypertension, in addition to a range of traditional risk factors. Thus, a study will be conducted on Syrian patients with hypertension and coronary artery disease to investigate some of the single polymorphisms in the apelin gene and its receptor that may be responsible for the development of these diseases, and to link the levels of this peptide and its receptor in the blood with these polymorphisms and the percentage of these diseases (as shown by many Modern Global Reference Studies).

Blood levels of apelin and its receptor will be determined in patients and controls, and correlated with hypertension and coronary artery disease. And the allelic and genotypic frequencies of the G212A single polymorphism nucleotide of the apelin receptor gene and the -1860T\>C single polymorphism nucleotide of the apelin gene in the study groups. And evaluation the functional role of A allele in hypertension. As well as investigating the association between: the genotypes of the apelin gene and the levels of apelin in the plasma, the genotypes of the apelin receptor gene and the levels of APJ in the plasma in the study groups. And link the polymorphism of the apelin gene with the polymorphism of the apelin receptor gene. And to determine the correlation between the presence of the studied SNPs and some traditional risk factors for coronary artery disease, which are age, hypertension, the onset age of hypertension, smoking, BMI, cholesterol and triglyceride levels in the blood, and family history of CAD.

Eligibility Criteria:
Inclusion Criteria:

* Control group: the subjects were characterized by no history of angina and other heart disease or hypertension, and do not have other chronic or inflammatory diseases.

They represent a normal resting ECG and normal exercise ECG stress testing. And the angiography showed the absence of any stenosis of the coronary arteries.

They were matched with CAD patients according to age, gender and ethnicity.

* CAD group with essential hypertension: the subjects were characterized by at least 70% stenosis in any coronary artery and high blood pressure (the average of three blood pressure readings was at least 140 mmHg systolic or 90 mmHg diastolic).
* CAD group without essential hypertension: the subjects were characterized by at least 70% stenosis in any coronary artery and normal blood pressure.
* Hypertension group without CAD: the subjects were characterized by the normal coronary artery and high blood pressure. And they were characterized by no history of angina and other heart disease or hypertension, and do not have other chronic or inflammatory diseases.

Exclusion Criteria:

* Individuals with valvular heart disease, cardiomyopathy, chronic kidney disease, diabetes, and inflammatory disease were excluded
Evaluation of Outcomes of Coronary Artery Bypass Grafting.

Evaluation of outcomes of coronary artery bypass grafting.

Evaluation of outcomes of coronary artery bypass grafting (CABG) on-, off- pump, pump assisted as well as bimammary coronary artery bypass grafting.

Objective:

To assess myocardial ischemic-reperfusion damage during different kinds of CABG.

To assess complications after during different kinds of CABG.

Eligibility Criteria:
Inclusion Criteria:

* Ischemic heart disease with indications for coronary artery bypass grafting.

Exclusion Criteria:

* valve disease
Soft Tissue Thickness on Submerged and Non Submerged Implants

Changes in the marginal bone level surrounding the implant are the frequently used parameters in assessing the short- and long-term success. Multiple biological and biomechanical factors have been reported to adversely affect marginal bone level. Recently, initial vertical mucosal tissue thickness has also been reported to have an impact on bone stability.The hypothesis of present study is that soft tissue thickness on implant placement has no positive impact of crestal bone remodeling.

The aim of this study is to evaluate the clinical and radiographical results of submerged and nonsubmerged implants with thin (\<3 mm) and thick (\>3 mm) soft tissue over 1.5 year after implant placement. All submerged and nonsubmerged implants were randomly placed as split-mouth. Clinical periodontal parameters were recorded. Crestal bone levels were analyzed from the day of implants inserted to 1.5 year after prosthetic loading on digitally standardized radiographs. Non-parametric test were used for statistically analysis.

Eligibility Criteria:
Inclusion Criteria:

* being older than 18 years of age
* generally healthy patients, no medical contraindication for implant surgery
* missing teeth in upper jaw posterior and more than one tooth in neighbourhood area
* no bone augmentation procedures before and during implant placement.

Exclusion Criteria:

* poor oral hygiene
* history of periodontitis
* smoking
* diabetes
* alcoholism
* taking medication which interferes soft and hard tissue healing
* bruxism.
The Effect of a Citrus Extract on Exercise Performance in Moderately Trained Athletes

In this study, the effect of citrus extract on exercise performance will be investigated. The study consists of three groups: one group will receive a high dose citrus extract, one group will receive a low dose citrus extract and the last group will receive a placebo. After four and eight weeks the effects on performance are measured through a Wingate cycling test. It is expected that exercise performance will increase in the citrus extract groups, compared to the placebo group.


Eligibility Criteria:
Inclusion Criteria:

* healthy idividuals
* Participants are amateur or (semi-) professional athletes in resistance or interval sports (engage in \>4 hours of intense physical activity per week).

Exclusion Criteria:

* Use of creatine supplements and/or anabolic steroids.
* Allergy to test product/placebo
* Allergy to citrus fruits
* BMI lower than 18 or higher than 30
* Recent muscle injury in less than one month before the start of the study.
* Cardiovascular complications
* Use of medication that may interfere with the study results
* Administration of investigational drugs or participation in any scientific intervention study which may interfere with this study (to be decided by the principle investigator), in the 180 days prior to the study.
* Abuse of products; alcohol (\> 20 alcoholic units per week) and drugs.
MINGO Supplemental Trial in X-linked Dystonia-Parkinsonism Patients

To see whether MINGO, a food supplement, will be able to lessen the drastic weight loss seen among X-linked Dystonia Parkinsonism patients.

X-linked dystonia parkinsonism (XDP, formerly known as DYT3) occurs primarily in Filipino males and is characterized by neurodegenerative dystonia and parkinsonism. It is currently recognized to have wide phenotypic variability relating to age of onset, location of disease onset and rate of severity/disease progression. Most patients begin with focal dystonia that generalizes with the development of parkinsonism later in disease course. XDP patients suffer from severe nutritional loss due to symptoms such as dysphagia, loss of appetite, and consistently high metabolic requirements brought about by their movement disorder. Approximately 79% of patients with XDP have experienced rapid weight loss since the onset of their disease. It is the aim of the researchers to assess the clinical usefulness of adding a nutritional supplement to the daily dietary needs of these patients.

MINGO is a supplement consisting of local ingredients such as moringa, rice and mung beans, which can be added to any type of edible paste, food, and liquid. Mingo has gained popularity as an emergency food in disaster relief operations due to the ease of its preparation, its high nutritional value and relatively low price. For the last two years, it has also been used as an agent for nutritional build up in malnourished populations of children. This study will provide valuable information on whether patients with XDP can increase their weight by consuming MINGO, which will lead to improvements in the patients' medical care and wellbeing.

Eligibility Criteria:
Inclusion Criteria:

* Subject is above the age of 18
* Positive Diagnosis of XDP by movement disorder specialist/fellow
* Subject with a yes response to a "supportive home environment" in the patient's most recent "doctors monthly report"
* Subject are easily accessible to passable roads and pubic transportation

Exclusion Criteria:

* Subjects who have extreme movements that prevent staff from performing BMI or MUAC measurements
* Subjects who have abnormal metabolic labs prior to the start of the study
* Subjects who are taking pharmacological or medicinal supplements that may effect weight
* Subjects who have been hospitalized within the last 2 weeks from the start of the trial
* Subjects who have a Nasogastric tube or G-tube
* Subjects with a history of other diseases that my effect weight (eg: hypo/hyperthyroidism)
Ejaculation Frequency and Semen Parameters

The goal of this observational study is to determine whether the frequency of ejaculation in men had an effect on semen parameters.. The main questions it aims to answer are:

* question 1：Whether the frequency of ejaculation has an effect on semen parameters
* question 2：Whether the penultimate abstinence period has an effect on semen parameters

The participants were men who underwent semen examination in the andrology clinic of the Reproductive Center of the First Hospital of Jilin University. A brief medical history was collected from each volunteer, including demographic information, fertility history and as well as information regarding their general health.The focus of the investigation is the time of abstinence for this examination, the penultimate abstinence period, and the number of ejaculation since the last 1 month.

The main subjects of this study were husbands who underwent semen examination, Including pre-conception, infertility, and his wife with a history of pregnancy loss. Before the examination, the basic information such as age, height, weight, smoking, drinking, infertility years, fertility and pregnancy history, marriage years, education, occupation and exclusion criteria have adverse effects on sperm were investigated.The focus of the investigation is the time of abstinence for this examination, the penultimate abstinence period, and the number of ejaculation since the last 1 month. According to World Health Organization standards, semen analysis requires abstinence for 48h to 7 days. Semen parameters were recorded, including sperm DNA fragmentation rate, sperm motility rate, total sperm count, sperm motility, and sperm morphology. The frequency of ejaculation was divided into four groups:(1)0-4 times/month;(2)5-8 times/month;(3) 8-12 times/month;(4) \>12 times/month.

Eligibility Criteria:
Inclusion Criteria:

1. Normal ejaculation function, normal sexual life, masturbation can ejaculate
2. Male age between 22 and 45 years old.
3. According to World Health Organization standards, the semen examination time is within 48h to 7 days of abstinence.

Exclusion Criteria:

1. The man was diagnosed with extremely severe oligospermia (sperm concentration \<1 million/ml) and azoospermia.
2. Identify the factors affecting semen parameters, long-term exposure to high temperature, long-term exposure to chemicals, heavy metals, radiation and other toxic and harmful substances, orchitis/epididymitis, cryptorchidism, radiotherapy and chemotherapy treatment, and taking drugs to improve sperm within three months
Normotensive and Hypertensive Placental Abruptions

Placental abruption is a significant cause of both maternal morbidity and neonatal morbidity and mortality. Most abruptions accept to be related to a chronic placental disease process. Therefore, it is very important to understand these processes. To analyze maternal and neonatal effects of placental abruption(PA) through a novel classification in the presence of hypertension. Initial hemoglobin parameters were also compared to predict pregnancy outcomes in addition to hypertension.

Objective: We aimed to classify placental abruption according to hypertension status.

Methods: This retrospective cohort designed study was conducted on 115 pregnant women with placental abruption. The main parameters scanned and recorded from the hospital database and patient medical files. Two groups were classified regarding of presence or absence of hypertension (53 hypertensive, 62 normotensive). Maternal demographical and clinical characteristics (abdominal pain, vaginal bleeding) were recorded. APGAR scores below 5 at 1 and 5 min., fetal or neonatal death, admission and length of stay in Neonatal Intensive Care Unit(NICU) were also investigated and compared between the groups.

Eligibility Criteria:
Inclusion Criteria:

* spontaneous,
* singleton pregnancies
* above 25 weeks of gestations with positive fetal cardiac activity

Exclusion Criteria:

* multiple gestations,
* presence of fetal or maternal infection,
* chronic inflammatory diseases or connective tissue disorders
* history of myocardial infarction,
* thrombosis
* history of steroid drug usage.
Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study

The purpose of this study is to test the effectiveness Secnidazole to treat recurrent BV. Secnidazole is approved for one-time use in acute BV. In this study, the drug will be used for recurrent BV, and given weekly for 18 weeks.

A single-center prospective pilot study with once-weekly oral secnidazole granule treatment of acute condition for two-weeks followed by prophylactic treatment of asymptomatic responders with once-weekly secnidazole for 16 weeks, followed by no therapy for 12 weeks. The final follow-up evaluation is at week 28.

Eligible women with a current symptomatic bacterial vaginosis infection (\> or = 3 Amsel criteria) and a history of at least 2 previous episodes of bacterial vaginosis in the past year will be enrolled in the open-label treatment study. All women will be treated with 2g of secnidazole granules orally once-weekly for 2 weeks. At the second visit, 3-5 days after completion of treatment, women who have a resolution of bacterial vaginosis (asymptomatic and \< or = 2 Amsel criteria) will continue on once-weekly secnidazole for 16 weeks.

Patients will be evaluated every 4 weeks for recurrence of bacterial vaginosis. This will include questions about symptoms as well as a pelvic examination for assessment of vaginal discharge (\> or = 3 Amsel criteria). We will also collect any information on other clinical evaluations for recurrence and the dates of diagnoses and types of treatments they may have received. Those who remain without recurrence during the 16-week suppressive phase will be followed for an additional 12 weeks off therapy, with assessment for recurrence at weeks 22 and 30. Throughout the study, data will be collected on participants' compliance and on the occurrence of adverse events.

Eligibility Criteria:
Inclusion Criteria:

* Ability to consent in English
* Current symptomatic bacterial vaginosis infection
* History of at least 2 previous episodes of bacterial vaginosis in the past year

Exclusion Criteria:

* Current gynecologic infection or condition, including candida vaginitis, gonorrhea, chlamydia, trichomonas, desquamative inflammatory vaginitis, atrophic vaginitis.
* Pre-existing heart conditions
* Pre-existing neurological conditions
* Currently Pregnant or breastfeeding
* Women taking anticoagulants, lithium, metoclopramide, or disulfiram therapy
* Hypersensitivity to secnidazole or other drugs in the same class.
A Study To Assess The Pharmacokinetics, Safety, And Tolerability Of A Pregabalin Controlled Release Formulation Administered Following Various Sized Caloric Meals As Compared To The Pregabalin Immediate Release Formulation

The purpose of this study is to (1) evaluate the effect of caloric intake on the pharmacokinetics of a single dose of a 330 mg pregabalin controlled release tablet relative to a 300 mg pregabalin immediate release capsule administered fasted and (2) determine the safety and tolerability of a single dose of a 330 mg pregabalin controlled release formulation administered following various sized caloric meals and the 300 mg pregabalin immediate release capsule administered fasted.

To assess the single dose pharmacokinetics, safety, and tolerability of pregabalin controlled release formulation following various sized caloric meals relative to the immediate release formulation.

Eligibility Criteria:
Inclusion Criteria:

* Healthy male or females
* Between the ages of 18 and 55 years, inclusive
* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2

Exclusion Criteria:

* Illicit drug use
* Pregnant or nursing females
* Females of childbearing potential who are unwilling or unable to use an acceptable method of contraception
China Diabetes Cognitive Dysfunction Early Diagnosis and Intervention Study (China-DECODE Study)

Type 2 diabetes (T2D) and dementia are both diseases with increasing incidence and prevalence globally, leading to substantial economic burdens for families and society. Notably, diabetes significantly increases the risk of cognitive dysfunction, which is classified into preclinical stage, mild cognitive impairment and dementia based on the disease severity. Cognitive dysfunction is a critical contributor to disability and mortality in elderly diabetes patients. Early diagnosis and intervention are crucial for delaying disease progression, enhancing treatment efficacy, and mitigating the impact of dementia. Currently, research and clinical management of cognitive dysfunction in individuals with diabetes are in their infancy, characterized by limitations such as single-center studies, limited sample sizes, inconsistent diagnostic criteria, and insufficient data sharing. Consequently, clinical diagnosis and treatment strategies are underdeveloped, medical staff's related knowledge is lacking, and potential therapeutic targets remain unexplored. In view of these problems and shortcomings, the population cohort study is supposed to be carried out based on accurate diagnosis and constructed the high standard information and sample bank. The study will establish the standard and quality system of T2D with cognitive dysfunction cohort study (unified standards and norms). The study will integrate the standard biological samples stratified acquisition function module (homogeneity and precision) of cognitive dysfunction in T2D, and complete the construction of biological samples bank and clinical diagnosis and treatment information database. The study will apply and develop brain structural and functional imaging technology to support precision diagnosis of cognitive dysfunction in T2D.

The neuropsychological test battery are used to access the cognitive function of subjects in the study. The laboratory examinations, brain MRI and olfactory function measurements will be done in the screening period. The samples such as plasma, serum, urine and faeces et al. of the subjects will be collected in the study.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥45 years;
* Type 2 diabetes diagnosed according to the American Diabetes Association criteria;
* Willingness and ability to complete systematic neuropsychological tests;
* Understanding of the research procedures and methods, potential benefits and risks of the trial, and sign written informed consent.

Exclusion Criteria:

* Fewer than 6 years of education;
* Left-handedness;
* Dementia;
* Acute metabolic complications such as diabetic ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemic coma within the previous 3 months;
* History or presence of neurological or psychiatric disorders;
* Presence of hypothyroidism;
* History of malignancy, or severe kidney or liver dysfunction.
The Role of NEWS on Intensive Care Discharges

To determine the ability of the NEWS at tertiary intensive care unit discharges to predict the development of clinical deterioration.

To determine a cut-off value for NEWS score for early readmission

The Nationaly Early Warning Score (NEWS) is a single score based on the measurement of vital signs and inspired gases by the patient. A higher NEWS indicates severity of illness and risk of adverse outcomes. The use of NEWS values to select the appropriate patients for tertiary ICU discharges has not been tested. Our aim is to test the value of NEWS on discharges tertiary ICU.

Eligibility Criteria:
Inclusion Criteria:

* Older than 18 years old
* Stay higher than 48 hours

Exclusion Criteria:

* Under 18 years old
* Stay lower than 48 hours
* Intoxication
* Exitus
Budesonide/Formoterol for Maintenance and Reliever Therapy Among Asthma Patients in Thailand

The purpose of this study is to determine the incidence of misuse, i.e., over-use and under-use, of Budesonide/formoterol for maintenance and reliever therapy in usual-care setting.


Eligibility Criteria:
Inclusion Criteria:

* Established persistent asthma
* Currently treated with Symbicort SMART for 3 months or longer

Exclusion Criteria:

* currently participating or have participated in a study with an investigational compound within the last 30 days
* current diagnosis of chronic obstructive pulmonary disease (COPD)
* smoked more than 10 pack-year
Telerehabilitation After Coronavirus

The aim of the study is to investigate the effects of telerehabilitation program on COVID-19 symptoms, quality of life, level of depression, perception of dyspnea, sleep, fatigue, kinesiophobia and patient satisfaction in individuals diagnosed with COVID-19.

Because of the risk of infection, telerehabilitation applications are recommended for patients with COVID-19. There are no studies in the literature evaluating the effectiveness of telerehabilitation program after COVID-19. In particular, the importance of the first eight weeks after the disease was emphasized.

It is thought that the telerehabilitation program will improve the functional capacities and quality of life of patients in order to adapt to the daily life after the infection more easily, to cope with the symptoms brought about by the disease more easily and to prevent the respiratory distress, intensive care stay and inactivity due to muscle weakness.

Eligibility Criteria:
Inclusion Criteria:

* volunteering to participate in the study
* at least once diagnosed with COVID-19,
* has a cognitive level that can adapt to online exercises,
* having a physical condition suitable for exercises
* staying in hospital due to covid-19

Exclusion Criteria:

* refuse to participate in the study
* having neurological, cardiac, respiratory disease that prevents exercise